Tae Life Sciences, a majority-owned subsidiary of Tae Technologies Inc., launched this week, forging ahead in development of its investigational accelerator-based platform hoped to treat head, neck and glioblastoma multiforme (GBM) cancer. Tae Life Sciences has licensed IP from Tae Technologies for the accelerator-based neutron beam technology for Boron Neutron Capture Therapy (BNCT), and aims to expand treatment capabilities for these difficult-to-address malignancies. In conjunction with its launch, Tae Life Sciences also inked a partnership deal with Neuboron Medtech Ltd. and closed a $40 million venture round. Read More
